{"id":"bermekimab-monoclonal-antibody","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL2109418","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Bermekimab binds to and neutralizes interleukin-1 beta (IL-1β), a central mediator of innate immune responses and inflammation. By inhibiting IL-1β signaling, the drug reduces the production of downstream inflammatory mediators and dampens excessive inflammatory responses. This mechanism is intended to treat conditions driven by IL-1β-mediated inflammation.","oneSentence":"Bermekimab is a monoclonal antibody that blocks IL-1β, a key pro-inflammatory cytokine, to reduce inflammation and immune activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:22:52.969Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory conditions (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT04021862","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-16","conditions":"Atopic Dermatitis, Eczema","enrollment":87},{"nctId":"NCT04988308","phase":"PHASE2","title":"A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-12","conditions":"Hidradenitis Suppurativa","enrollment":151},{"nctId":"NCT03512275","phase":"PHASE2","title":"A Study of Bermekimab in Patients With Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-06-20","conditions":"Hidradenitis Suppurativa","enrollment":42},{"nctId":"NCT01767857","phase":"PHASE3","title":"A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-03-31","conditions":"Metastatic Colorectal Cancer","enrollment":643},{"nctId":"NCT03496974","phase":"PHASE2","title":"A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-21","conditions":"Atopic Dermatitis","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Bermekimab Monoclonal Antibody","genericName":"Bermekimab Monoclonal Antibody","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bermekimab is a monoclonal antibody that blocks IL-1β, a key pro-inflammatory cytokine, to reduce inflammation and immune activation. Used for Inflammatory conditions (Phase 2 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}